Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. / Morze, Jakub; Wittenbecher, Clemens; Schwingshackl, Lukas; Danielewicz, Anna; Rynkiewicz, Andrzej; Hu, Frank B.; Guasch-Ferré, Marta.
In: Diabetes Care, 2022, p. 1013–1024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies
AU - Morze, Jakub
AU - Wittenbecher, Clemens
AU - Schwingshackl, Lukas
AU - Danielewicz, Anna
AU - Rynkiewicz, Andrzej
AU - Hu, Frank B.
AU - Guasch-Ferré, Marta
PY - 2022
Y1 - 2022
N2 - BACKGROUNDDue to the rapidly increasing availability of metabolomics data in prospective studies, an update of the meta evidence on metabolomics and type 2 diabetes risk is warranted.PURPOSETo conduct an updated systematic review and meta-analysis of plasma, serum, and urine metabolite markers and incident type 2 diabetes.DATA SOURCESWe searched PubMed and Embase until 6 March 2021.STUDY SELECTIONWe selected prospective observational studies where investigators used high-throughput techniques to investigate the relationship between plasma, serum, or urine metabolites and incident type 2 diabetes.DATA EXTRACTIONBaseline metabolites per-SD risk estimates and 95% CIs for incident type 2 diabetes were extracted from all eligible studies.DATA SYNTHESISA total of 61 reports with 71,196 participants and 11,771 type 2 diabetes cases/events were included in the updated review. Meta-analysis was performed for 412 metabolites, of which 123 were statistically significantly associated (false discovery rate–corrected P < 0.05) with type 2 diabetes risk. Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates and energy-related metabolites (mannose, trehalose, and pyruvate), acylcarnitines (C4-DC, C4-OH, C5, C5-OH, and C8:1), the majority of glycerolipids (di- and triacylglycerols), (lyso)phosphatidylethanolamines, and ceramides included in meta-analysis were associated with higher risk of type 2 diabetes (hazard ratio 1.07–2.58). Higher levels of glycine, glutamine, betaine, indolepropionate, and (lyso)phosphatidylcholines were associated with lower type 2 diabetes risk (hazard ratio 0.69–0.90).LIMITATIONSSubstantial heterogeneity (I2 > 50%, τ2 > 0.1) was observed for some of the metabolites.CONCLUSIONSSeveral plasma and serum metabolites, including amino acids, lipids, and carbohydrates, are associated with type 2 diabetes risk.
AB - BACKGROUNDDue to the rapidly increasing availability of metabolomics data in prospective studies, an update of the meta evidence on metabolomics and type 2 diabetes risk is warranted.PURPOSETo conduct an updated systematic review and meta-analysis of plasma, serum, and urine metabolite markers and incident type 2 diabetes.DATA SOURCESWe searched PubMed and Embase until 6 March 2021.STUDY SELECTIONWe selected prospective observational studies where investigators used high-throughput techniques to investigate the relationship between plasma, serum, or urine metabolites and incident type 2 diabetes.DATA EXTRACTIONBaseline metabolites per-SD risk estimates and 95% CIs for incident type 2 diabetes were extracted from all eligible studies.DATA SYNTHESISA total of 61 reports with 71,196 participants and 11,771 type 2 diabetes cases/events were included in the updated review. Meta-analysis was performed for 412 metabolites, of which 123 were statistically significantly associated (false discovery rate–corrected P < 0.05) with type 2 diabetes risk. Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates and energy-related metabolites (mannose, trehalose, and pyruvate), acylcarnitines (C4-DC, C4-OH, C5, C5-OH, and C8:1), the majority of glycerolipids (di- and triacylglycerols), (lyso)phosphatidylethanolamines, and ceramides included in meta-analysis were associated with higher risk of type 2 diabetes (hazard ratio 1.07–2.58). Higher levels of glycine, glutamine, betaine, indolepropionate, and (lyso)phosphatidylcholines were associated with lower type 2 diabetes risk (hazard ratio 0.69–0.90).LIMITATIONSSubstantial heterogeneity (I2 > 50%, τ2 > 0.1) was observed for some of the metabolites.CONCLUSIONSSeveral plasma and serum metabolites, including amino acids, lipids, and carbohydrates, are associated with type 2 diabetes risk.
U2 - 10.2337/dc21-1705
DO - 10.2337/dc21-1705
M3 - Journal article
C2 - 35349649
SP - 1013
EP - 1024
JO - Diabetes Care
JF - Diabetes Care
SN - 0149-5992
ER -
ID: 347755451